ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

DeMets Receives Lectureship On Epidemiology From NIH.

May 4, 2001

HHS Pick For FDA May Be Food Safety Expert.

October 5, 2001

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Five Awards Expected In Annual CCP Review; 21 Applicants Compete For Limited Funding

February 1, 1991

NSABP Agrees To Three-Month Search for Chairman Candidates, Review Of Plans

June 10, 1994

In Brief: Travel Grants available For 14th International Congress; NIH Seeks Nurses For Study Sections

November 22, 1985